Clinical and immunological effects of hydroxychloroquine in patients with active rheumatoid arthritis despite antirheumatic treatment
Clinical and immunological effects of hydroxychloroquine in patients with active rheumatoid arthritis despite antirheumatic treatment
复制标题
羟氯喹对接受抗风湿治疗的活动性类风湿关节炎患者的临床和免疫学影响
DOI：
10.1093/mr/roac153
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Kaneko Y.
中科院分区：
文献类型：
--
作者：
Takei H;Takanashi S;Otomo K;Hanaoka H;Kikuchi J;Yamaoka K;Yoshimoto K;Abe T;Takeuchi T;Kaneko Y.
目的探讨羟氯喹（HCQ）在类风湿关节炎（RA）患者中的疗效和安全性。除既往治疗外，还给予HCQ 24周。主要终点是患者的比例，实现美国流变学学院（ACR）20在第24周，相比，倾向评分匹配的历史对照group.ResultsSixty例患者入组，并给予HCQ。我们还确定了276例患者作为历史对照组的候选人。倾向评分匹配产生每组46例患者。HCQ组第24周达到ACR 20的患者比例显著高于对照组（54.4% vs. 28.3%，P = 0.007）。HCQ组第24周达到ACR 50和ACR 70的患者比例也高于对照组（ACR 50，30.4% vs. 4.3%，P = 0.006; ACR 70，17.4% vs. 0%，P = 0.005）。HCQ视网膜病变，也没有任何新的安全信号，观察在study.ConclusionThe除了HCQ的csDMARDs是有效的，没有新的安全信号在RA患者。
ObjectivesTo investigate the efficacy and safety of hydroxychloroquine (HCQ) in patients with rheumatoid arthritis (RA).MethodsPatients with active RA, despite conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), were recruited. HCQ was administered for 24 weeks, in addition to prior treatment. The primary end-point was the proportion of patients achieving American College of Rheumatology (ACR) 20 at Week 24, compared to that of a propensity score–matched historical control group.ResultsSixty patients were enrolled and administered HCQ. We also identified 276 patients as candidates for the historical control group. Propensity score matching yielded 46 patients in each group. The proportion of patients achieving ACR20 at Week 24 was significantly higher in the HCQ group than in the control group (54.4% vs. 28.3%,P= .007). The proportion of patients achieving ACR50 and ACR70 at Week 24 were also higher in the HCQ group than in the control group (ACR50, 30.4% vs. 4.3%,P= .006; ACR70, 17.4% vs. 0%,P= .005). Neither HCQ retinopathy nor any new safety signal was observed during the study.ConclusionThe addition of HCQ to csDMARDs was effective, with no new safety signal in patients with RA.